We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio PD-1 inhibitors, as well as BRAF and MEK ...

A report reviews the case of a patient with stage IV melanoma who, while having several issues with treatment toxicity, was later free of disease following treatment with BRAF and MEK inhibitors. BRAF ...

Targeted BRAF-MEK inhibition resulted in a response in nearly all patients with untreated BRAF V600E–mutated papillary craniopharyngioma, according to results from a small phase II study. Of 16 ...

Please provide your email address to receive an email when new articles are posted on . Most patients treated with BRAF and MEK inhibitors for histiocytic disorders showed no active disease.

Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets, approved by FDA as single-agent therapies Issued: 29 ...

A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma. Patient-reported outcomes of patients treated with (neo)adjuvant immune checkpoint combination therapy ...

SAN FRANCISCO — Biliary tract cancers (BTCs) are rare, aggressive malignancies that generally have a poor prognosis, and are usually treated with chemotherapy. A new study shows that in a subgroup of ...

Based on a retrospective meta-analysis of clinical trial data, authors of a recent paper in JAMA Oncology concluded that BRAF/MEK and programmed death receptor-1 (PD-1) inhibitors were the most ...

Phase III studies of single agent therapy in metastatic melanoma with BRAF V600 mutations meet primary endpoints Findings from GlaxoSmithKline (GSK) plc's Phase III clinical study programme evaluating ...

“This is the first report of spindle cell sarcoma BRAF V600E/S607T double-mutated, responding to a combination of B-Raf and MEK inhibitors.” “This is the first report of spindle cell sarcoma BRAF ...

Single-agent BRAF-inhibitor therapy has a proven survival benefit for patients with advanced-stage melanoma and is approved for this indication; however, downsides of this approach are early acquired ...